Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 20Thoracic 2Sarcoma 2Gynecologic 2Gastrointestinal 2Dermatologic 2NET 1Lymphoid 1Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 73Pheochromocytoma 8Gastro-enteropancreatic neuroendocrine tumor 8Paraganglioma 7Carcinoma, Neuroendocrine 7Carcinoid Tumor 7Adenoma, Islet Cell 7Thyroid Neoplasms 5Sarcoma 5Pancreatic Neoplasms 5Neoplasms 5Melanoma 5Breast Neoplasms 5Prostatic Neoplasms 4Neuroblastoma 4Neoplasm Metastasis 4Mesothelioma 4Carcinoma, Merkel Cell 4Carcinoma 4Stomach Neoplasms 3Ovarian Neoplasms 3Neuroectodermal Tumors, Primitive 3Meningioma 3Liver Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Central Nervous System Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Medullary 3

Interventions

cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × NET × 90 days × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡